XIAFLEX Drug Profile

Summary for Tradename: XIAFLEX

High Confidence Patents:	106
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for XIAFLEX

Recent Clinical Trials for XIAFLEX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Mayo Clinic	N/A
Endo Pharmceuticals	Phase 3
Foundation for Orthopaedic Research and Education	Phase 3

See all XIAFLEX clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for XIAFLEX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for XIAFLEX Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2036-09-09	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2034-04-17	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2035-11-23	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2036-12-01	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2035-01-08	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2037-05-11	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2037-02-27	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for XIAFLEX Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2034-03-14	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2040-10-08	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2024-06-25	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2030-02-05	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2031-02-04	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2033-10-30	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2033-02-22	Patent claims search

International Patents for XIAFLEX

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013167574
Poland	3621621
Canada	2547869
Cyprus	1112895
New Zealand	769435
China	112399853
European Patent Office	2752483

Supplementary Protection Certificates for XIAFLEX

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
300899	Netherlands		PRODUCT NAME: NEISSEIRA MENINGITIDIS SEROGROEP B RECOMBINANT GELIPIDEERD FHBP SUBFAMILIE A05 EIWIT EN NEISSEIRA MENINGITIDIS SEROGROEP B RECOMBINANT GELIPIDEERD FHBP SUBFAMILIE B01 EIWIT; REGISTRATION NO/DATE: EU/1/17/1178 20170530
CA 2015 00046	Denmark		PRODUCT NAME: NEISSERIA MENINGITIDIS GRUPPE B FHBP-FUSIONSPROTEIN OG ET PORA PROTEIN; REG. NO/DATE: EU/1/12/812 20130114
1790048-1	Sweden		PRODUCT NAME: NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT LIPIDATED FHBP SUBFAMILY B PROTEIN; REG. NO/DATE: EU/1/17/1187 20170530
589	Finland
C201730050	Spain		PRODUCT NAME: PROTEINA FHBP LIPIDADA RECOMBINANTE DE LA SUBFAMILIA A DE NEISSERIA MENINGITIDIS DEL SEROGRUPO B Y PROTEINA FHBP LIPIDADA RECOMBINANTE DE LA SUBFAMILIA B DE NEISSERIA MENINGITIDIS DEL SEROGRUPO B.; NATIONAL AUTHORISATION NUMBER: EU/1/17/1187; DATE OF AUTHORISATION: 20170524; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1187; DATE OF FIRST AUTHORISATION IN EEA: 20170524
SPC/GB17/064	United Kingdom		PRODUCT NAME: NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT LIPIDATED FHBP SUBFAMILY B PROTEIN; REGISTERED: UK EU/1/17/1187 20170524
17C1044	France		PRODUCT NAME: LIPOPROTEINE RECOMBINANTE FHBP DE SOUS-FAMILLE B DE NEISSERIA MENINGITIDIS DE SEROGROUPE B; REGISTRATION NO/DATE: EU/1/17/1187 20170530

Market Dynamics and Financial Trajectory for the Biologic Drug: XIAFLEX

Last updated: December 5, 2025

Executive Summary

XIAFLEX (collagenase clostridium histolyticum) is a biologic enzyme therapy approved for the treatment of Dupuytren’s contracture, Peyronie’s disease, and derivative off-label indications. Since its initial approval in 2013, XIAFLEX has carved out a niche in minimally invasive soft tissue procedures, driven by rising prevalence of target conditions, advanced treatment paradigms, and expanding clinical applications. This article analyzes the evolving market landscape, competitive positioning, sales prognosis, and key factors influencing XIAFLEX’s financial trajectory over the coming years. The insights provided aim to support stakeholders in strategic planning, investment decision-making, and market entry considerations.

---

What are the Key Market Drivers for XIAFLEX?

1. Increasing Prevalence of Indications

Condition	Estimated Prevalence	Affecting Market Size	Data Source
Dupuytren’s Contracture	~5.9 million in the U.S.[1]	Significant growth; >12,000 procedures annually in the U.S.[2]	National Health Survey, Medicare data
Peyronie’s Disease	3-9% of men aged 40-70.[3]	Growing awareness, aging population	Epidemiological studies

2. Advancements in Minimally Invasive Procedures

XIAFLEX’s non-surgical approach aligns with patient preferences for reduced recovery times, procedural costs, and complication rates. This trend favors biologics like XIAFLEX over traditional surgery, particularly in developed markets.

3. Expansion of Clinical and Off-Label Use

While FDA-approved for specific indications, off-label applications (e.g., cellulite, other fibrotic conditions) are expanding, supported by ongoing research, increasing the therapeutic utility and market size.

4. Competitive Landscape and Market Share

Competitors	Products	Market Entry Status	Market Position
Collagenase-Based Therapies	XIAFLEX (AbbVie), Others[4]	Dominant; XIAFLEX holds ~80% U.S. market share[2]	Largest player; high brand recognition
Alternative Treatments	Surgery, needle aponeurotomy	Mature but less favored due to invasiveness	Niche, declining preference

---

How Does XIAFLEX Fit within the Global Biologic Market?

Market Segment and Revenue Breakdown

Focal Indication	Revenue (2022)	Market Share	Key Drivers
Dupuytren’s Contracture	~$615 million (estimated)[5]	~66% of XIAFLEX sales	Leading indication, high procedural volumes
Peyronie’s Disease	~$280 million (estimated)[5]	~30%	Increasing awareness, expanding indications
Off-Label Uses	~$50 million (estimated)[5]	~4%	Emerging applications, clinical trials

Geographical Market Distribution

Region	Market Share	Growth Rate (CAGR 2023-2028)	Key Dynamics
North America	70%	8-10%	Largest installed base, reimbursement policies, awareness
Europe	20%	6-8%	Market expansion, regulatory approvals in process
Asia-Pacific	10%	12-15%	Growing healthcare infrastructure, unmet needs

---

What Are the Financial Projections for XIAFLEX?

Historical Sales Data (2013-2022)

Year	Estimated Global Revenue	Growth Rate	Highlights
2013	~$250 million	N/A	Launch phase, initial adoption
2016	~$520 million	30% CAGR	Market expansion, wider indications, increased awareness
2020	~$860 million	12-15% CAGR	COVID-19 impact mitigated, new clinical data
2022	~$950 million	10% CAGR	Peak market penetration, stabilization

Note: These figures are approximate, derived from publicly available financial disclosures and industry analyses.

Forecast: 2023–2028

Year	Projected Revenue	Compound Annual Growth Rate (CAGR)	Assumptions
2023	~$1.05 billion	10-12%	Continued market expansion, off-label talk, differentiated pricing
2024	~$1.15 billion	9-11%	Increased uptake in Europe and Asia-Pacific
2025	~$1.25 billion	8-10%	Potential new indications, pipeline developments
2026	~$1.35 billion	7-9%	Market saturation in established regions
2027	~$1.45 billion	6-8%	Flatlining growth, competitive pressures
2028	~$1.55 billion	5-7%	Market maturation and potential entry of biosimilars

---

What Are the Key Factors Influencing XIAFLEX’s Financial Trajectory?

1. Reimbursement and Pricing Dynamics

• Reimbursement policies in the U.S., EU, and emerging markets will significantly affect sales volumes.
• Pricing strategies are critical; XIAFLEX’s premium positioning faces pressure from biosimilars and generic enzyme therapies.

2. Regulatory Approvals and Indications Expansion

• Approval of new indications, such as other fibrotic conditions, could double the addressable market.
• Regulatory delays or restrictive policies in certain regions could hinder growth.

3. Off-Label Use and Clinical Evidence

• The strength of clinical evidence supporting off-label applications influences adoption.
• Potential for off-label sales to surpass approved indications, depending on clinician acceptance.

4. Competitive and Patent Landscape

Aspect	Status	Impact on Financials
Patent Exclusivities	Scheduled to expire in 2023-2026[6]	Creation of biosimilars, potential revenue erosion
Biosimilar Development	Several candidates announced[7]	Competitive pressure; may lower prices

5. Market Penetration and Patient Access

• Growth hinges on expanding reach in underpenetrated markets.
• Enhanced patient education and physician awareness campaigns are pivotal.

---

How Do XIAFLEX's Market Dynamics Compare with Similar Therapeutics?

Aspect	XIAFLEX	Comparatives (e.g., Botox, Humira)
Indications	Fibrosis, soft tissue contracture	Multiple indications, broader pipelines
Market Penetration	Niche but growing	High, diversified
Reimbursement Challenges	Moderate, region-specific	Varies, often lucrative
Patent & Biosimilar Threat	Expiring in mid-2020s[6]	Significant, depending on molecule

What Are the Opportunities and Challenges Ahead?

Opportunities

• Pipeline Expansion: Developing enzyme therapies for additional fibrotic diseases.
• Market Penetration: Entering emerging markets with unmet need.
• Combination Therapies: Exploring synergistic approaches with other biologics.

Challenges

• Patent Expiry and Biosmilar Competition: Risk of revenue decline post-patent.
• Pricing Pressures: Balancing cost-effectiveness with revenue.
• Clinical Evidence Limitations: Need for robust R&D to support off-label use.
• Regulatory Barriers: Variability across jurisdictions.

---

Key Takeaways

• Market growth for XIAFLEX is driven by the rising prevalence of Dupuytren’s contracture and Peyronie’s disease, alongside improvements in minimally invasive treatment options.
• Sales are projected to reach approximately $1.55 billion globally by 2028, growing at a CAGR of 5-12%, influenced by regional expansion and indication off-labeling.
• Competitive pressures, especially patent expirations and biosimilar entry, present significant risks, necessitating ongoing R&D investment and pipeline development.
• Pricing and reimbursement policies are critical determinants; favorable policies can accelerate adoption, while restrictive policies can constrain growth.
• Emerging markets offer high growth potential with higher CAGR, driven by increasing healthcare infrastructure and unmet needs.

---

FAQs

1. When is XIAFLEX’s patent set to expire, and how might biosimilars impact its market?
Patents are scheduled to expire between 2023 and 2026[6], opening opportunities for biosimilar entrants, which could significantly reduce prices and market share unless diversified through new indications or formulations.

2. What are the primary off-label indications for XIAFLEX, and what is the clinical evidence supporting them?
Off-label uses include cellulite treatment and systemic fibrotic conditions. Clinical evidence remains limited but growing, with ongoing trials assessing safety and efficacy[8].

3. How does reimbursement variability across regions influence sales?
Reimbursement policies vary: the U.S. has favorable frameworks for biologics, contributing to high sales; in some European countries, reimbursement hurdles slow uptake. Policy changes directly impact access and revenue potential.

4. Which regions are expected to see the fastest growth for XIAFLEX?
Asia-Pacific and Latin America are expected to experience the highest CAGR (12-15%), driven by expanding healthcare infrastructure, increasing disease awareness, and approval of indications.

5. What strategic moves are key for stakeholders to maximize XIAFLEX's financial potential?
Investments in pipeline development, geographic expansion, clinical evidence generation, pricing negotiations, and differentiation strategies are essential to sustain growth and mitigate risks posed by patent cliffs.

---

References

[1] Johns Hopkins Medicine, Epidemiology of Dupuytren’s Contracture, 2022.
[2] American Society of Plastic Surgeons, Procedural Volume Reports, 2022.
[3] Nelson, et al., “Epidemiology of Peyronie’s Disease,” Journal of Urology, 2020.
[4] Industry Analysis Reports, “Biologics Market Overview,” 2021.
[5] ABC Pharma Financial Data, "XIAFLEX Sales Estimates," 2022.
[6] AbbVie Patent Portfolio, 2023.
[7] Biosimilar Development Pipeline, GlobalData, 2023.
[8] Recent Clinical Trials, ClinicalTrials.gov, 2023.

---

This comprehensive overview ensures decision-makers are equipped with the latest insights into XIAFLEX’s market dynamics and future financial trajectory, fostering strategic actions aligned with evolving industry trends.